Why Zai Lab’s latest lung cancer collaboration matters for shareholders

Zai Lab (ZLAB) has drawn fresh attention after reporting ongoing progress in its Phase 3 DLLEVATE trial for ZL-1310 in small cell lung cancer and unveiling a new global clinical collaboration with Amgen.

Recent updates around the DLLEVATE trial and the Amgen tie up come after a 30 day share price return of 12.57% and a year to date share price return of 19.33%. This is set against a 1 year total shareholder return decline of 29.99%, which keeps longer term sentiment cautious even as shorter term momentum has picked up.

If this small cell lung cancer story has caught your attention, it can be useful to see what else is happening in related areas of healthcare. You can broaden your search by checking a curated list of 31 healthcare AI stocks

With Zai Lab’s shares down on a 1 year and multi year basis, but recently rebounding and trading below some analyst valuation estimates, you need to ask whether this setup hints at a buying opportunity or a market already pricing in future growth.

Most Popular Narrative: 58.2% Undervalued

Based on the most followed narrative, Zai Lab’s fair value of $49.49 sits well above the last close at $20.68. This frames the current debate around how much future growth is already reflected in the price.

Analysts are assuming Zai Lab's revenue will grow by 51.7% annually over the next 3 years.

Analysts assume that profit margins will increase from 49.7% loss today to 16.7% in 3 years time.

Want to see what justifies such rapid revenue expansion and a sharp swing to profits? The narrative leans on aggressive sales growth and a richer margin profile, along with a future earnings multiple that would put Zai Lab alongside faster growing peers. The details behind those assumptions are where the story really gets interesting.

Result: Fair Value of $49.49 (UNDERVALUED)

However, the story could shift quickly if competition in key oncology markets bites harder than expected or if China pricing and reimbursement decisions undercut revenue potential.

Next Steps

With sentiment split between concern and optimism, this is a good moment to look at the numbers yourself and act before views settle. To see the full balance of potential upsides and key watchpoints, start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If this story has sharpened your interest, do not stop here. Your next smart move could be waiting in another corner of the market.

• Target potential upside by scanning a focused list of mispriced opportunities using the 58 high quality undervalued stocks.
• Prioritise sleep at night potential by checking companies filtered for resilient profiles through the 72 resilient stocks with low risk scores.
• Hunt for lesser known opportunities that still show strong foundations with the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.